A case of late distant recurrence/metastasis (≧10 years after curative surgery) of anaplastic lymphoma kinase-rearranged lung cancer and the review of similar cases in the literature

Publication date: November 2020Source: Human Pathology: Case Reports, Volume 22Author(s): Shohei Matsuo, Yoshitane Tsukamoto, Eiichiro Mabuchi, Shunichi Negoro, Seiichi Hirota
Source: Human Pathology: Case Reports - Category: Pathology Source Type: research

Related Links:

This study aimed to comprehensively analyze the characteristics, treatment patterns, and survival outcomes of non-small-cell lung cancer (NSCLC) patients initially diagnosed with brain metastases (BMs) in real-world practice.MethodsWe enrolled NSCLC patients initially diagnosed with BMs between Jan 2004 and Jan 2018 in our institution. Patient demographics, treatment modalities, and survival outcomes were then analyzed. Brain localized treatment (BLT) included early brain radiotherapy (EBR), deferred brain radiotherapy (DBR), and surgery.ResultsA total of 954 patients were identified. Concerning initial treatment, 525 pati...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: In vitro experiments revealed that the Renshenwuweizi decoction-induced decrease in A549 cell proliferation was achieved by inducing apoptosis and S-phase cell cycle arrest via the p53 pathway. These findings provide the experimental basis for Renshenwuweizi decoction treatment of lung cancer. PMID: 33000577 [PubMed - in process]
Source: Journal of Traditional Chinese Medicine - Category: Complementary Medicine Authors: Tags: J Tradit Chin Med Source Type: research
We report the rechallenge of camrelizumab therapy in two patients previously treated with microwave ablation (MWA) and camrelizumab. Although objective responses were achieved, camrelizumab therapy was discontinued because of the development of immune-related pneumonia (IRP). Treatment with camrelizumab was reinitiated after the patients recovered from IRP. The reoccurrence of more severe IRP necessitated additional corticosteroid therapy. The rechallenge of camrelizumab in patients treated with MWA plus camrelizumab regimen and who developed IRP should be cautious.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Anaplastic lymphoma kinase (ALK) gene rearrangement counts for approximately 5 % –7 % of non-small cell lung cancer (NSCLC) [1]. This kind of fusion represents a distinct mechanism of driver mutation in NSCLC. More than 19 different fusion partners have been identified in cancer patients [2]. The fusion of echinoderm microtubule-associated protein like 4 (EML4) and ALK is the most common fusion pattern, which occurred in at least 80 % ALK positive lung cancers [3,4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ng-We Kim Pemetrexed is currently mainly considered for the treatment of advanced nonsquamous non-small-cell lung cancer (NSCLC) negative for gene mutations/rearrangements (wild-type disease (WTD)). This narrative review aimed to highlight the role of pemetrexed in the treatment of onco-driven nonsquamous advanced NSCLC by reviewing published clinical studies. For epidermal growth factor receptor (EGFR) mutations, patient survival following first-line pemetrexed–platinum was longer than for WTD. Later-line pemetrexed-based treatment after tyrosine kinase inhibitor (TKI) failure provided greater benefits than ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a ...
Source: Oncology (Williston Park, N.Y.) - Category: Cancer & Oncology Authors: Tags: Oncology (Williston Park) Source Type: research
Conclusion: This study highlights that the adenocarcinoma incidence is surpassing squamous cell carcinoma in Indian lung cancer patients also, as observed in Western population. Mean age at diagnosis is about one decade earlier than in the Western population. Driver mutations are more common in India than in the West as also reported in other Asian studies.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: EGFR/ALK co-alterations in adenocarcinomas albeit rare do exist. The challenge of monetary hurdle in developing countries with ALK TKI therapy can be handled by giving only EGFR TKI in these cases of concomitant mutations. Future perspective in research could be finding an agent with the potential of dual inhibition of ALK and EGFR.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
AbstractTreatment stratification in stage IV NSCLC is guided by identification of oncogene driver mutations. Actionable mutations with current licenced therapeutic agents include epidermal growth factor receptor (EGFR), rearrangements of anaplastic lymphoma kinase (ALK), ROS-1 and BRAF V600. Alongside progress with small molecule therapy, developments in immune checkpoint inhibitors (CPIs) have transformed the landscape of stage III and stage IV NSCLC. The success of CPIs has led to evaluation with small molecule therapy in both concurrent and sequential settings. In this review we summarise recent results of combination C...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Funding Opportunity RFA-CA-20-053 from the NIH Guide for Grants and Contracts. Projects to be Served by Pipeline The proposed analytical network will serve to understand the data generated by CCG programs as well as collaborations with other divisions: The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) Exceptional Responders (ER, in collaboration with DCTD) Clinical Trials Sequencing Program (CTSP, in collaboration with DCTD) Carcinomas of Unknown Primary (CUPP) Refractory Cancers (Peripheral T-Cell Lymphomas, Recurrent GBMs) This resource that can be utilized by any NCI project th...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
More News: Cancer | Cancer & Oncology | Lung Cancer | Lymphoma | Pathology